Enlivex announced the dosing of the first patient at a United States clinical site in the Phase 2b clinical trial of Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENLV:
- Enlivex Faces Nasdaq Minimum Bid Price Deficiency After Shares Fall Below $1 Threshold
- 3 Best Cheap Stocks to Buy Now: 04/29/26
- Enlivex Therapeutics files to sell 23.33M ordinary shares for holders
- Enlivex Secures Danish Approval for Global Phase 2b Trial of Allocetra in Knee Osteoarthritis
- Enlivex receives CTA approval by DKMA for Phase 2b trial of Allocetra